Moreover, this therapy can modulate expression levels of tumor antigens used as targets for CAR-T cell treatment, such as NKG2D ligands, that are induced by ionizing radiation [50], and it potentially could be used in combination with NKG2D CAR-T cells for the treatment of triple-negative breast cancer [51]. This evidence concerns the gene KLRK1 and triple-negative breast carcinoma.